Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan
Pembrolizumab is a cost-effective first-line treatment for advanced NSCLC with PD-L1 TPS ≥ 50% in Japan. Nivolumab plus ipilimumab is also a viable option. Atezolizumab is the least cost-effective.
Authors
- Y Kimura
- Jumpei Taniguchi (ORCID: https://orcid.org/0000-0003-2480-9018)
- Chanon Nusawat (ORCID: https://orcid.org/0009-0009-2716-3727)
- So Sato
- Hideo Yasunaga
Institutions
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1007/s10198-026-01912-9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00